Coronavirus Vaccine Contender CureVac Launches $200M IPO
German biopharmaceutical company CureVac, which is working on a coronavirus vaccine, said Monday that it hopes to raise $200 million in an initial public offering led by Davis Polk and NautaDutilh....To view the full article, register now.
Already a subscriber? Click here to view full article